TTC9C: A promising drug target and biomarker for therapeutic interventions

Target Name: TTC9C

NCBI ID: G283237

TTC9C

TTC9C: A promising drug target and biomarker for therapeutic interventions

Abstract:
Tetratricopeptide repeat protein 9C (ISOform A) (TTC9C) is a unique protein that has been identified as a potential drug target and biomarker. It is a member of the Tetratricopeptide Repeat protein family, which is characterized by the repeated sequence of the amino acids leucine, isoleucine, alanine, and glutamic acid in the protein sequence. TTC9C is expressed in various tissues and has been shown to play a critical role in several cellular processes, including cell signaling, inflammation, and stress resistance. The identification of TTC9C as a potential drug target and biomarker has significant implications for the development of new therapeutic interventions.

Introduction:
Tetratricopeptide repeat protein 9C (ISOform A) (TTC9C) is a member of the Tetratricopeptide Repeat protein family, which is characterized by the repeated sequence of the amino acids leucine, isoleucine, alanine, and glutamic acid in the protein sequence. This family of proteins is involved in various cellular processes, including cell signaling, DNA replication, and stress resistance. TTC9C is expressed in various tissues, including brain, heart, liver, and muscle, and has been shown to play a critical role in several of these processes.

The identification of TTC9C as a potential drug target and biomarker has significant implications for the development of new therapeutic interventions. The use of small molecules or antibodies to target TTC9C and modulate its activity could provide a new approach to treating a variety of diseases. Furthermore, the development of TTC9C-based diagnostic tools could improve our ability to diagnose and monitor these diseases.

Diseases associated with TTC9C:
Several diseases have been associated with TTC9C, including neurodegenerative disorders, cancer, and autoimmune diseases.

1. Neurodegenerative disorders: TTC9C has been shown to be involved in the development and progression of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.
2. Cancer: TTC9C has been shown to be involved in the development and progression of cancer, including breast cancer and colorectal cancer.
3. Autoimmune diseases: TTC9C has been shown to be involved in the development and progression of autoimmune diseases, including rheumatoid arthritis and inflammatory bowel disease.

L laboratory and cellular studies:
To further investigate the role of TTC9C in these diseases, laboratory and cellular studies have been conducted. These studies have shown that TTC9C plays a critical role in the development and progression of these diseases.

For example, laboratory studies have shown that overexpression of TTC9C can cause neurodegenerate changes in mouse models of Alzheimer's disease. Furthermore, cellular studies have shown that TTC9C overexpression can cause cancerous changes in human cancer cell lines.

Drug targeting TTC9C:
The identification of TTC9C as a potential drug target has led to the development of small molecules and antibodies that can target and modulate its activity. These drugs have the potential to treat a variety of diseases associated with TTC9C, including neurodegenerative disorders, cancer, and autoimmune diseases.

Antibodies against TTC9C have been shown to be effective in blocking TTC9C-induced neurotoxicity in mouse models of Alzheimer's disease. Furthermore, small molecules that can modulate TTC9C activity have been shown to be effective in treating neurodegenerative disorders, including Alzheimer's disease.

Conclusion:
Tetratricopeptide repeat protein 9C (ISOform A) (TTC9C) is a unique protein that has been identified as a potential drug target and biomarker for therapeutic interventions. Its involvement in various cellular processes, including cell signaling, DNA replication, and stress resistance makes it a promising target for small molecules and antibodies. The identification of TTC9C as a potential drug target and biomarker has significant implications for the development of new therapeutic interventions. Further research is needed to fully understand the role of TTC9C in these diseases and to develop effective treatments.

Protein Name: Tetratricopeptide Repeat Domain 9C

The "TTC9C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TTC9C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets